The G2 checkpoint is a quality-control step that prevents a cell from dividing until its DNA is intact and fully copied. It sits between the G2 phase (the gap after DNA replication) and mitosis (when the cell physically splits in two). If the checkpoint detects damaged or incompletely replicated DNA, it halts the cycle and gives the cell time to make repairs. If the damage is too severe, the cell can be routed toward programmed death instead.
Where G2 Fits in the Cell Cycle
A typical human cell that divides every 24 hours spends roughly 11 hours in G1 (growing and preparing to copy DNA), 8 hours in S phase (actually copying DNA), 4 hours in G2, and about 1 hour in mitosis. G2 is the final preparation window before division. During these four hours, the cell checks that every chromosome has been accurately duplicated and that no breaks or errors remain from the replication process or from environmental damage like radiation or toxic chemicals.
How the Checkpoint Decides to Stop or Go
The decision to enter mitosis depends on a single molecular switch: a protein complex made of CDK1 and cyclin B. When this complex is fully active, it triggers mitosis. When it’s held in an inactive state, the cell stays in G2. The checkpoint controls this switch through a “double lock” system involving two opposing enzymes. One enzyme (Wee1) adds a chemical tag to CDK1 that keeps it switched off. The other (Cdc25) removes that tag, turning CDK1 on.
Under normal conditions, once DNA replication finishes, CDK1 activity starts low and gradually builds throughout G2 until it reaches a threshold that launches mitosis. But when the checkpoint detects DNA damage, it simultaneously boosts the braking enzyme and suppresses the activating enzyme. This double lock ensures the cell cannot accidentally slip into division with broken chromosomes.
The Damage Sensors
Cells detect DNA problems through a signaling relay. The G2 checkpoint relies primarily on two sensor proteins, ATR and CHK1, which are especially sensitive to the kinds of damage that arise during or after DNA replication, such as single-strand breaks and stalled replication forks. When ATR detects a problem, it activates CHK1, which then enforces the double lock on CDK1. This is different from the G1 checkpoint earlier in the cycle, which depends more heavily on a separate pair of sensors (ATM and CHK2) and on the tumor suppressor protein p53.
That said, p53 plays a role at G2 as well. It can enforce G2 arrest by lowering the cell’s levels of cyclin B1, the partner protein CDK1 needs to trigger mitosis. Without enough cyclin B1, CDK1 simply cannot reach the activity threshold required for division. This gives p53 checkpoint authority at multiple points in the cell cycle, though its mechanisms differ at each stage.
Repair, Then Resume
The G2 arrest is not meant to be permanent. Once the cell’s repair machinery fixes the DNA damage, the checkpoint releases its hold. CHK1 signaling drops, the braking enzyme loses its grip on CDK1, and the activating enzyme flips CDK1 back on. CDK1 activity then rises exponentially, pushing the cell into mitosis. This recovery process is tightly controlled because resuming division too early, before repairs are truly finished, can be just as dangerous as never stopping at all.
If the damage is extensive or irreparable, the cell may instead activate programmed cell death (apoptosis). The choice between repair and death depends on the severity of the damage and the balance of pro-survival and pro-death signals within the cell. p53 is one of the key arbiters of this decision, capable of both pausing the cycle and initiating the death program.
Why It Matters for Cancer
The G2 checkpoint is one of the body’s main defenses against genomic instability, the accumulation of mutations and chromosome errors that drives cancer. When cells enter mitosis carrying damaged DNA, they risk producing daughter cells with the wrong number of chromosomes (aneuploidy) or with mutations that get passed on permanently. Research published in Nature’s Oncogenesis journal found that dysregulation of the G2 checkpoint recovery pathway reduced DNA repair efficiency and correlated strongly with increased chromosomal instability across several cancer types.
Many cancers have already lost their G1 checkpoint, often through mutations in p53 or related proteins. These cancer cells become even more dependent on the G2 checkpoint as their last remaining safety net before division. This dependency has made the G2 checkpoint an attractive drug target. If you disable the G2 checkpoint in cancer cells that already lack a functional G1 checkpoint, those cells are forced into mitosis with unrepaired DNA and often die as a result.
G2 Checkpoint Drugs in Development
The most advanced drug strategy targets Wee1, the braking enzyme that keeps CDK1 inactive during G2 arrest. Blocking Wee1 forces cells through the checkpoint before their DNA is repaired. As of recent clinical trial data, 79 trials involving five different Wee1-blocking drugs have been registered, with one compound alone accounting for 61 of those trials. Results have shown promise in colorectal cancer patients with specific mutations, in glioblastoma (where the drug successfully crossed the blood-brain barrier), and in ovarian and pancreatic cancers when combined with chemotherapy or radiation.
The strategy works best in tumors that are already missing other checkpoint defenses, particularly p53 mutations. Normal healthy cells, which still have intact G1 checkpoints, can catch DNA damage earlier and are less vulnerable to Wee1 inhibition. This selectivity is what makes the approach viable: it exploits a weakness unique to cancer cells rather than poisoning all dividing cells equally.